Spyre Therapeutics (SYRE) Cash from Investing Activities: 2015-2025
Historic Cash from Investing Activities for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to $25.0 million.
- Spyre Therapeutics' Cash from Investing Activities fell 41.51% to $25.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.6 million, marking a year-over-year increase of 69.45%. This contributed to the annual value of -$353.3 million for FY2024, which is 225.93% down from last year.
- Per Spyre Therapeutics' latest filing, its Cash from Investing Activities stood at $25.0 million for Q3 2025, which was down 68.36% from $79.0 million recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Cash from Investing Activities registered a high of $79.0 million during Q2 2025, and its lowest value of -$170.5 million during Q4 2024.
- Over the past 3 years, Spyre Therapeutics' median Cash from Investing Activities value was -$61,000 (recorded in 2025), while the average stood at -$32.5 million.
- As far as peak fluctuations go, Spyre Therapeutics' Cash from Investing Activities soared by 801.33% in 2023, and later tumbled by 1,882.81% in 2024.
- Spyre Therapeutics' Cash from Investing Activities (Quarterly) stood at $9.7 million in 2021, then spiked by 44.88% to $14.0 million in 2022, then plummeted by 351.94% to -$35.3 million in 2023, then tumbled by 383.51% to -$170.5 million in 2024, then tumbled by 41.51% to $25.0 million in 2025.
- Its Cash from Investing Activities stands at $25.0 million for Q3 2025, versus $79.0 million for Q2 2025 and -$61,000 for Q1 2025.